Cargando…
How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review
BACKGROUND: Despite the increasing economic assessment of biomarker-guided therapies, no clear agreement exists whether existing methods are sufficient or whether different methods might produce different cost-effectiveness results. This study aims to examine current practices of modeling companion...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408935/ https://www.ncbi.nlm.nih.gov/pubmed/34470603 http://dx.doi.org/10.1186/s12885-021-08725-4 |